Default Category
-
Measuring Impairment at Dofasco
Mary Gillett; Mary-Jane MastrandreaCase IVEY-9B09B017-EAccounting and ControlIn December 2008, the ArcelorMittal Dofasco (Dofasco) accounting team was facing a significant challenge. In the past few years, Dofasco had undergone significant ownership changes, and when the firm had first been acquired the market had placed a premium share value on the Dofasco subsidiary. In light of a recent economic downturn, the accounting team was required to reassess the values assigned to the subsidiary's net assets. Dismal forecasted ...Starting at €8.20
-
Canopy Growth Corporation: Accounting Problems in the Cannabis Industry?
Mary Gillett; Morgan HartCase IVEY-9B21B007-EAccounting and ControlIn November 2019, John Fowler, founder and principle of consulting firm Blaise Ventures (Blaise) had been listening to a conference call where the management of Canopy Growth Corporation (Canopy) had reported its financial results for its second quarter ended September 30, 2019. Cannabis companies faced a wide array of complex financial reporting issues, and Fowler felt that being able to understand these issues and explain them to clients was cr...Starting at €8.20
-
Blackberry 10
Mary Gillett; Morgan HartCase IVEY-9B15B008-EAccounting and ControlIn 2014, a well-reputed innovative technology company had introduced a new operating system and two new smartphone devices with the goal of turning around the company’s slumping hardware sales. Despite positive product reviews in the media, the models did not sell as well as expected. Consequently, the lower demand led to impairment of inventory and supply commitments at various times throughout the following fiscal year. At the end of the fiscal...Starting at €8.20
-
Accounting at Biovail - Revised
Mary Gillett; Mary-Jane Mastrandrea; Jessica FrischCase IVEY-9B09B004-EAccounting and ControlBiovail was a large international pharmaceutical company with reported revenues of $788 million. Banc of America has issued a research report which indicates that Biovail Corporation's financial statements raised a number of issues that warrant caution for investors, and as a result, Biovail's stock was given a sell rating by Banc of America. A member of Biovail's audit committee is preparing for an upcoming audit meeting and considers the implic...Starting at €8.20